{"nctId":"NCT00660010","briefTitle":"Study of Lupron Depot In The Treatment of Central Precocious Puberty","startDateStruct":{"date":"1991-01"},"conditions":["Puberty, Precocious"],"count":55,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Lupron (leuprolide acetate)"]}],"interventions":[{"name":"Lupron (leuprolide acetate)","otherNames":["Lupron"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of isosexual central precocious puberty with onset of Tanner scores of Stage II for breast or pubic hair earlier than age 8.0 years in girls or Stage II for pubic hair or genitalia earlier than 9.0 years in boys.\n* Confirmation of diagnosis by a pubertal response to a gonadotropin-releasing hormone (GnRH) stimulation test (LH \\> 10 U/L at baseline).\n* Chronological age less than 9.0 years in girls or less than 10.0 years in boys at time of first dosing.\n* Bone age advanced at least 1 year beyond the chronological age at entry into the study.\n* The condition may be idiopathic or secondary to another lesion. If secondary, therapy of the primary condition will have been undertaken and stabilized.\n* No evidence of abnormal pituitary, adrenal, thyroid and gonadal function except for premature secretion of gonadotropins.\n\nExclusion Criteria:\n\n* Irradiation to the central nervous system.\n* Prior therapy with medroxyprogesterone acetate and/or with any GnRH analog (including prior treatment with daily subcutaneous and depot formulations of leuprolide acetate).","healthyVolunteers":false,"sex":"ALL","maximumAge":"10 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)","description":"Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations","description":"Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":"21.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"3.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"5.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.73"}]}]}]},{"type":"SECONDARY","title":"Mean Stimulated Estradiol Concentrations in Females","description":"Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"18.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"6.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Mean Stimulated Testosterone Concentrations in Males","description":"Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"347.7","spread":"121.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"12.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":"7.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"6.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":"11.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":"19.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":"19.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"17.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","spread":"24.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"17.16"}]}]}]},{"type":"SECONDARY","title":"Mean Ratio of Bone Age to Chronological Age","description":"Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.11"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Posttreatment Height (ht.) Compared to Standard Population and as Predicted From Ht. at Baseline (BL)","description":"Height was measured by stadiometer and was standardized for age according to standard growth charts. A standardized score of 0 indicated a mean ht. equivalent to mean of a standard population from 2000 CDC standardized ht. charts. Height gain was calculated as ht. - predicted ht. from the Bayley-Pinneau method on the basis of bone age at baseline. Final adult ht. was determined by measurement at final adult ht., if available, or by ht. collected during the follow-up period associated with a growth velocity \\<1 cm/year or a bone age \\>14 yrs in females or \\>15 yrs in males.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"5.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"5.05"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Time to or Mean Age at Regular Menses in Females After Treatment","description":"Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding and was defined by the investigator's clinical judgment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":"0.89"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Female Subjects Who Reported Regular Menses at Adulthood","description":"Subjects were required to complete final adult questionnaire to provide information on adult reproductive function. Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects Who Reported Pregnancies at Final Questionnaire","description":"The final questionnaire was completed by 20 females who were at least 18 years of age. The subjects reported on total number of pregnancies resulting in live births or number of miscarriages (spontaneous or elective) and whether the subject was currently pregnant.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Pregnancies Reported by Subjects at Final Questionnaire","description":"The final questionnaire was completed by 20 female subjects who were at least 18 years of age. The total number of pregnancies were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)","description":"Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":55},"commonTop":["Pharyngitis","Headache","Flu syndrome","Rash","Cough increased"]}}}